RIDDLE&CODE is Partnering With Influx Technology to Develop the Next Generation of its Drive&Stake Stack
RIDDLE&CODE is partnering with Influx Technology LTD to develop the next generation of its Drive&Stake stack. This collaboration focuses on the further evolution of Drive&Stake hardware to transform vehicles into autonomous agents in a new era of mobility.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220602005047/en/
RIDDLE&CODE and Influx Technology are working together to build a powerful and flexible toolchain for original equipment manufacturer (OEM) developers in the automotive ACES (Automated, Connected, Electric and Shared) space to prototype peer-to-peer (P2P) blockchain-based solutions.
With three decades of experience and expertise in developing business-to-business (B2B) automotive embedded systems and deep in-vehicle communication protocol, Influx Technology will help RIDDLE&CODE create the next generation of Drive&Stake hardware.
"The goal is to manufacture a toolchain that reduces complexity and simplifies experimentation, enabling a more significant focus on value-added business models whilst ensuring vehicle safety and security," says Steve Ratheram, Senior R&D Engineer | Automotive Embedded at RIDDLE&CODE.
"Bringing together the automotive industry experience of Influx and the industrial Web3.0 vision of RIDDLE&CODE," says Minh Cao, Director of Mobility at RIDDLE&CODE, "the consortium engineers industry-grade hardware connected to a banking grade distributed ledger technology (DLT) infrastructure that finally transforms any vehicle into an autonomous economic agent and its drivers into data entrepreneurs."
About the Drive&Stake Consortium
The Drive&Stake consortium continues to realise its goal of creating decentralised and secure technologies, focusing on blockchain and cryptography. The D&S stack comprises reference hardware that connects vehicle embedded systems data to a secure exchange-to-exchange (E2E) data & token management system.
In addition to the new hardware, the Drive&Stake Consortium will lead to the following:
- The development of new data economies and vehicle lifecycle revenue streams
- The creation of secure provenance of trustful data
- The development of collaborative and decentralised data-driven business models
- The sharing of data and relevant information between competitors without revealing industry secrets
- Benefit from the network growth through a token-economical business model that governs and grows the network using incentives
- Gain access to the required backend technology stack to enable the rollout of all business processes on the platform in a regulatory compliant way
About RIDDLE&CODE
RIDDLE&CODE is Europe’s leading company for blockchain interface solutions. The company develops hardware and software stacks that combine the security of smart cards with blockchain and the Internet of Things (IoT). Together with its tier-one clients and partners, which include Daimler Mobility, BMW, Wien Energie and leading Dutch crypto exchange LiteBit, RIDDLE&CODE brings new business models to the fintech, energy, mobility and materials industries.
More information: www.riddleandcode.com
About Influx Technology
INFLUX TECHNOLOGY is the leading global name in vehicle CAN bus data logging providing innovative engineering solutions. Our global teams are dedicated to designing modular and flexible solutions that are intuitive to use, manufactured to a high standard with quality post-sale support.
More information: www.influxtechnology.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220602005047/en/
Contact information
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD7.1.2026 13:30:00 EET | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for COMP360, enabling the initiation of a late-stage clinical trial in patients with PTSD. Compass management, along with KOL and industry leaders, will host a webinar today to discuss the company’s clinical trial plans for PTSD, as well as commercial preparations for treatment-resistant depression (TRD) from 10:00-11:30 am ET on January 7th. “PTSD is one of the most challenging mental health conditions, with approximately 13 million adults in the U.S. living with persistent symptoms and limited treatment options,” said Dr. Guy Goodwin, Chief Medical Officer at Compass Pathways. “We are pleased to advance our clinical development - the unmet need is profound, and it demands bold innovation. We believe COMP360 has the potential to tra
Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 12:07:00 EET | Press release
Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,
ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 11:00:00 EET | Press release
CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including
I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety7.1.2026 10:00:00 EET | Press release
I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works. This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that underpin public safety, mobility and economic activity. Ramudden operates in markets where demand is steady and growing and benefits from deep commerci
RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta7.1.2026 10:00:00 EET | Press release
RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service agreement, BOOST Pharma has transferred its manufacturing process to RoslinCT’s state-of-the-art facilities in Edinburgh, Scotland. The partnership will progress toward GMP manufacturing of starting materials and clinical drug product, supporting Phase III clinical development of BT-101. The therapy is an allogeneic mesenchymal stem cell (MSC) product designed to address the underlying cause of OI at the earliest stages of life. BOOST Pharma was founded on pioneering science originating from Karolins
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom